A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and
efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of
care in participants with PPF over 52 weeks.
Age: 18 years - 66+
Gender: All
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the
efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary
fibrosis (BEACON-IPF).
Age: 40 years - 66+
Gender: All
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Age: 21 years - 66+
Gender: All
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the safety and tolerability of oral
daily administration of TTI-101 over a 12-week treatment duration in participants with
idiopathic pulmonary fibrosis (IPF).
Age: 40 years - 66+
Gender: All
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic,
radiation). The safety and efficacy of oral ifetroban will be assessed in patients with
IPF.
Age: 40 years - 66+
Gender: All
Renal Allograft Fibrosis Study
Despite the reduction in acute rejection episodes in renal transplant patients due to
modern immunosuppression, proportionate improvements in long-term allograft survival have
not been achieved. Virtually any disease or injury affecting renal allografts can
culminate...
Age: 18 years - 66+
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider
liver transplantation as an option, even if controversial. In sicker recipients, LT
results in immediate survival, but poor medium-term survival rates in some studies. The
scarcity...
Age: 18 - 80 years
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of...
Age: 18 - 80 years
Gender: All
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of
recombinant human pentraxin-2 (rhPTX-2; PRM-151) administered by intravenous (IV) infusion to
participants with idiopathic pulmonary fibrosis (IPF).
Age: Birth - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747)
can lead to histological improvement in fibrosis with no worsening of NASH in adults with
compensated cirrhosis due to NASH.
Age: 18 years - 66+
Gender: All
Standardized Treatment of Pulmonary Exacerbations II
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during
which symptoms of lung infection increase and lung function decreases. These pulmonary
exacerbations are treated with varying antibiotics for varying time periods based on need...
Age: 18 years - 66+
Gender: All